Three shareholders in beauty treatment firm Q-Med (QMED.ST) rejected a $970 million bid from L'Oreal (OREP.PA) and Nestle (NESN.VX), putting pressure on the the joint venture to raise its price. Buying Q-Med would give the venture, called Galderma, access to the Swedish firm's Restylane product, an alternative to Botox for smoothing out wrinkles and making faces look plumper and younger. Galderma, already has acceptances for its offer from Q-Med's largest shareholder, Lyftet Holding, which has 47.5 percent.
Source
